LORANIB lorlatinib 25mg 30'S Approval No. 11 L 0935/22 Expiration Date 05-12-2025

Lorlatinib Tablets

【 Generic Name 】Lorlatinib Tablets

【 Brand Name 】LORANIB

【 Main Ingredients 】 Lorlatinib……….25 mg.

【 Indications 】

For the treatment of patients with anaplastic lymphoma kinase (ALK) or ROS1-positive metastatic non-small cell lung cancer.

【 Usage and Dosage 】

Oral administration. Recommended dose: 100 mg once a day. For patients with severe renal impairment, 75 mg once a day.

[ Contraindications ] Use in combination with strong CYP3A inducers.

【 Notes 】

1. Central Nervous System (CNS) Effects: Withhold and resume at same or reduced dose.
2. Hyperlipidemia, atrioventricular block: suspend or reduce the dose.
3. Interstitial lung disease/pneumonitis: Discontinue medication immediately in patients who develop ILD/pneumonitis.
4. Embryo-Fetal Toxicity: Can cause fetal harm. Inform patients of the potential risk to the fetus.

[ Adverse Reactions ] Edema, peripheral neuropathy, cognitive effects, dyspnea, fatigue, weight gain, joint pain, mood effects and headache.

【 Properties 】White tablets.

【 Validity period 】2 years from the date of production.

【 Packaging 】30 tablets/bottle.

【 Storage 】

• Keep away from light and store in a cool and dry place (not exceeding 30℃).
• Keep out of reach of children.